Cytokinetics, Incorporated (CYTK) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

mode. After the speaker's remarks, we will open the call to questions. We will allow for one question per participant. If you would like to ask a question during this time, simply press the star followed by the number one on your telephone keypad. If you would like to withdraw your question, please press the star one again. I would now like to turn the call over to Diane Weiser, Platykinetics Senior Vice President of Corporate Affairs. Please go ahead. Good afternoon, and thanks for joining us on the call today. Robert Blum, President and Chief Executive Officer, will begin with an overview of the quarter and recent developments. Andrew Kellis, EVP and Chief Commercial Officer, will address commercial readiness activities for Affy Campton. Betty Malek, EVP of R&D, will provide updates related to the clinical development program and medical affairs activities for Affy Campton. Stuart Kupfer, SVP and Chief Medical Officer, will provide updates on the clinical development program for Omicamp and CK586, which is now called Eulacamp. Emily, EVP and Chief Financial Officer, will provide a financial overview of the past quarter. And finally, Robert will provide closing comments and review our expected key milestones for the remainder of 2025. Please note that portions of the following discussion, including our responses to questions, contain statements that relate to future events and performance, rather than historical facts and constitute forward-looking statements. Our actual results might differ materially from those projected in these forward-looking statements. Additional information concerning factors that could cause our actual results to differ materially from those in these forward-looking statements is contained in our SEC filings, including our current report re...